CURELINE BALTIC IMPLEMENTS EUROPEAN UNION CO-FUNDED STUDY ON NOVEL IN VIVO SCREENING TOOLS USING CELLULAR BARCODING TECHNOLOGY
Vilnius, Lithuania, August 10, 2022 – Cureline Baltic’s expertise in preclinical project management services will be on full display as it implements a study seeking to develop novel high-throughput in vivo screening methods to validate oncology drug candidates.
The exciting new project entitled, “Development of innovative high-throughput in vivo screening technology for validation of oncology drug candidates using a novel cellular double barcoding technology” will be co-financed by the European Regional Development Fund, as part of its Operational Programme for EU Investments in Lithuania.
Precision medicine studies focused on hematopoietic stem cells (HSCs) and their use in advanced therapy medicinal product (ATMP) development constitute an area of intense growth and potential, particularly for oncologic applications. While it is currently possible to conduct in vivo tracking of single HSC fates, existing methods are inefficient, limited to processing a few dozen clones at a time. Cellular barcoding makes use of unique identifiers, called “barcodes”, to tag individual cells on a larger scale. The Cureline Group’s research expertise and excellent track record were keys to Cureline Baltic’s selection as one of the EU Investment Fund’s grant recipients, which aims to boost research and innovation in Lithuania.
Project implementation period is from November 2021 until August 2023. Stay tuned for more updates!
